Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report

Noguchi,Eiichiro; Kamio,Takako; Kamio,Hidenori; Miura,Hiroko; Tamaki,Masako; Nishizawa,Masako; Aoyama,Kei; Oochi,Tetsuya; Kameoka,Shingo

doi:10.3892/ol.2014.2594

Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report

Authors:
- Eiichiro Noguchi
- Takako Kamio
- Hidenori Kamio
- Hiroko Miura
- Masako Tamaki
- Masako Nishizawa
- Kei Aoyama
- Tetsuya Oochi
- Shingo Kameoka
View Affiliations

Affiliations: Department of Surgery II, Tokyo Women's Medical University, Tokyo 162-8666, Japan
Published online on: October 9, 2014 https://doi.org/10.3892/ol.2014.2594
Pages: 2448-2452

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The case of a 72-year-old female who identified a lymph node enlargement in the left axilla is reported in the present study. A lymph node biopsy revealed a metastatic adenocarcinoma of the axillary lymph node. Following various assessments, the patient was diagnosed with occult breast cancer and lymph node metastases, for which treatment was initiated. Trastuzumab monotherapy was administered as the patient was elderly, positive for the hepatitis B virus and exhibited the following immunostaining/immunohistochemical analysis results: Estrogen receptor (ER) negative (-), progesterone receptor (PgR) negative (-) and human epidermal growth factor receptor 2 (HER2) positive (3+). Breast ultrasonography was performed 10 months after the initial trastuzumab administration and the left axillary lymph node enlargement had reduced in size and severity. However, a skin rash (erythema) was observed encompassing the left breast and extending into the axilla. As determined by the result of a skin biopsy of this area, the patient was diagnosed with occult breast cancer with cutaneous metastases. The immunohistochemical analysis results obtained from the skin biopsy were similar to those obtained from the lymph nodes: ER (-), PgR (-) and HER2 (3+). Therefore, the patient was switched from trastuzumab to lapatinib monotherapy. The erythema completely disappeared after two months of treatment. At present (34 months following lapatinib monotherapy initiation) no new lesions or severe side‑effects have been observed.

View Figures

View References

1	Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001.
2	Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment: the M77001 study group. J Clin Oncol. 23:4265–4274. 2005.
3	Burstein HJ, Harris LN, Marcom PK, et al: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 21:2889–2895. 2003.
4	Di Leo A, Gomez HL, Aziz Z, et al: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 26:5544–5552. 2008.
5	Fourquet A, Meunier M and Campana F: Occult Primary Cancer with Axillary Metastases. Disease of the Breast. Harris JR, Lippman ME, Morow M and Osborne CK: 3rd edition. Lippincott Williams & Wilkins; Philadelphia, PA: pp. 1047–1052. 2004
6	Kaklamani V and Gradishar WJ: Axillary node metastases with occult primary breast cancer. http://www.uptodate.com/. Accessed December 2, 2013
7	Blanchard DK and Farley DR: Retrospective study of women presenting with axillary metastases from occult breast carcinoma. World J Surg. 28:535–539. 2004.
8	Copeland EM and McBride CM: Axillary metastases from unknown primary sites. Ann Surg. 178:25–27. 1973.
9	Sobin LH, Gospodarowicz MK and Wittekind C: International Union Against Cancer (UICC) TNM classification of malignant tumours. 7th edition. Wiley-Liss; New York, NY: 2009
10	Tsubouchi H, Kumada H, Kiyosawa K, et al: Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection: Joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis. Kanzo. 50:38–42. 2009.
11	Lüftner D, Cheli C, Mickelson K, et al: ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer. Int J Biol Markers. 19:175–182. 2004.
12	Scaltriti M, Verma C, Guzman M, et al: Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 28:803–814. 2009.
13	Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20:719–726. 2002.
14	Baselga J, Carbonell X, Castañeda-Soto N-J, et al: Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 23:2162–2171. 2005.
15	Gomez HL, Doval DC, Chavez MA, et al: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 26:2999–3005. 2008.
16	Kaufman B, Mackey JR, Clemens MR, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM Study. J Clin Oncol. 27:5529–5537. 2009.
17	Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 27:5538–5546. 2009.
18	Rimawi MF, Mayer IA, Forero A, et al: Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 31:1726–1731. 2013.
19	Baselga J, Cortés J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 366:109–119. 2012.
20	Swain SM, Kim SB, Cortés J, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 14:461–471. 2013.